Form 4: Candel Therapeutics Director Joseph Papa Acquires Over 64,000 Shares in Direct Offering

Candel Therapeutics, Inc. Director Joseph C. Papa acquired 64,239 shares of common stock through a registered direct offering at $4.67 per share, held indirectly by his revocable living trust.

Summary

• Joseph C. Papa, a Director of Candel Therapeutics, Inc. (CADL), acquired 64,239 shares of common stock.
• The acquisition occurred on June 25, 2025.
• The shares were purchased at a price of $4.67 per share.
• This transaction was part of a registered direct offering by the Issuer, pursuant to a Securities Purchase Agreement dated June 23, 2025.
• The shares are held indirectly by the Joseph C. Papa Revocable Living Trust, for which the Reporting Person serves as trustee.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director signals confidence in the company's future, which is generally viewed positively by the market.

Positives

• A director, Joseph C. Papa, acquired a significant number of shares (64,239), which can signal confidence in the company's future prospects.
• The acquisition was part of a registered direct offering, indicating the company successfully raised capital.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The shares are held indirectly by the Joseph C. Papa Revocable Living Trust, which is wholly owned by a trust for which the Reporting Person serves as trustee.

Stakeholder Impact

• Shareholders may view the director's share acquisition as a positive indicator of management's belief in the company's value.

Next Steps

• NA

Key Dates

Recommendation

Keywords

Candel Therapeutics, CADL, Joseph C. Papa, Director, Insider Trading, Stock Acquisition, Form 4, SEC Filing, Registered Direct Offering, Common Stock